vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Civeo Corp (CVEO). Click either name above to swap in a different company.
Civeo Corp is the larger business by last-quarter revenue ($161.6M vs $83.5M, roughly 1.9× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -4.0%, a 10.8% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 7.1%). Civeo Corp produced more free cash flow last quarter ($14.5M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
BLLN vs CVEO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $161.6M |
| Net Profit | $5.7M | $-6.5M |
| Gross Margin | 69.9% | 22.7% |
| Operating Margin | 11.5% | -0.1% |
| Net Margin | 6.8% | -4.0% |
| Revenue YoY | 117.4% | 7.1% |
| Net Profit YoY | 138.3% | 58.1% |
| EPS (diluted) | $0.10 | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $161.6M | ||
| Q3 25 | $83.5M | $170.5M | ||
| Q2 25 | — | $162.7M | ||
| Q1 25 | — | $144.0M | ||
| Q4 24 | — | $151.0M | ||
| Q3 24 | $38.4M | $176.3M | ||
| Q2 24 | — | $188.7M | ||
| Q1 24 | — | $166.1M |
| Q4 25 | — | $-6.5M | ||
| Q3 25 | $5.7M | $-455.0K | ||
| Q2 25 | — | $-3.3M | ||
| Q1 25 | — | $-9.8M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | $-14.9M | $-5.1M | ||
| Q2 24 | — | $8.2M | ||
| Q1 24 | — | $-5.1M |
| Q4 25 | — | 22.7% | ||
| Q3 25 | 69.9% | 25.7% | ||
| Q2 25 | — | 25.3% | ||
| Q1 25 | — | 20.4% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | 52.6% | 21.4% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | — | -0.1% | ||
| Q3 25 | 11.5% | 4.1% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | -3.8% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | -32.9% | 0.0% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | — | -1.1% |
| Q4 25 | — | -4.0% | ||
| Q3 25 | 6.8% | -0.3% | ||
| Q2 25 | — | -2.0% | ||
| Q1 25 | — | -6.8% | ||
| Q4 24 | — | -10.2% | ||
| Q3 24 | -38.8% | -2.9% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | -3.1% |
| Q4 25 | — | $-0.58 | ||
| Q3 25 | $0.10 | $-0.04 | ||
| Q2 25 | — | $-0.25 | ||
| Q1 25 | — | $-0.72 | ||
| Q4 24 | — | $-1.04 | ||
| Q3 24 | $-1.47 | $-0.36 | ||
| Q2 24 | — | $0.56 | ||
| Q1 24 | — | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $14.4M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $174.4M |
| Total Assets | $327.5M | $477.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.4M | ||
| Q3 25 | $195.2M | $12.0M | ||
| Q2 25 | — | $14.6M | ||
| Q1 25 | — | $28.4M | ||
| Q4 24 | — | $5.2M | ||
| Q3 24 | — | $17.9M | ||
| Q2 24 | — | $7.4M | ||
| Q1 24 | — | $16.8M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $43.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $174.4M | ||
| Q3 25 | $-239.5M | $182.5M | ||
| Q2 25 | — | $209.4M | ||
| Q1 25 | — | $220.7M | ||
| Q4 24 | — | $236.4M | ||
| Q3 24 | $-242.9M | $282.2M | ||
| Q2 24 | — | $297.4M | ||
| Q1 24 | — | $297.4M |
| Q4 25 | — | $477.4M | ||
| Q3 25 | $327.5M | $491.1M | ||
| Q2 25 | — | $508.8M | ||
| Q1 25 | — | $423.8M | ||
| Q4 24 | — | $405.1M | ||
| Q3 24 | — | $477.6M | ||
| Q2 24 | — | $483.2M | ||
| Q1 24 | — | $513.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $19.3M |
| Free Cash FlowOCF − Capex | $6.5M | $14.5M |
| FCF MarginFCF / Revenue | 7.7% | 8.9% |
| Capex IntensityCapex / Revenue | 8.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $19.3M | ||
| Q3 25 | $13.8M | $13.8M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-8.4M | ||
| Q4 24 | — | $9.5M | ||
| Q3 24 | — | $35.7M | ||
| Q2 24 | — | $32.4M | ||
| Q1 24 | — | $6.0M |
| Q4 25 | — | $14.5M | ||
| Q3 25 | $6.5M | $8.2M | ||
| Q2 25 | — | $-6.8M | ||
| Q1 25 | — | $-13.7M | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | — | $28.2M | ||
| Q2 24 | — | $27.0M | ||
| Q1 24 | — | $372.0K |
| Q4 25 | — | 8.9% | ||
| Q3 25 | 7.7% | 4.8% | ||
| Q2 25 | — | -4.2% | ||
| Q1 25 | — | -9.5% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 16.0% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | 3.0% | ||
| Q3 25 | 8.8% | 3.3% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 4.2% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.93× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
CVEO
Segment breakdown not available.
